How frequent are invasive therapies required in patients receiving tamsulosin for benign prostatic hyperplasia? A retrospective long-term study
スポンサーリンク
概要
- 論文の詳細を見る
- 2006-02-01
著者
-
KUBOTA Kiyoshi
Department of Pharmacoepidemiology, Faculty of Medicine, University of Tokyo
-
HOMMA YUKIO
Department of Urology, University of Tokyo
-
Homma Yukio
Department Of Urology Faculty Of Medicine The University Of Tokyo
-
KAWABE Kazuki
Tokyo Teishin Hospital
-
Sozu Takashi
Department Of Industrial Management And Engineering Faculty Of Engineering Tokyo University Of Scien
-
Kubota Kiyoshi
Department Of Pharamacoepidemiology University Of Tokyo Faculty Of Medicine
-
Kubota Kiyoshi
Department Of Pharmacoepidemiology Faculty Of Medicine The University Of Tokyo
関連論文
- Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial : a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effec
- Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial : a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effec
- Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation : Five-year results
- Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer
- Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation
- Preoperative Endocrine Therapy for Clinical Stage A_2, B, and C Prostate Cancer: An Interim Report on Short-Term Effects
- Estimate Criteria for Efficacy of Treatment in Benign Prostatic Hyperplasia
- Estimate Criteria for Diagonsis and Severity in Benign Prostatic Hyperplasia
- Estrogen receptor-binding fragment-associated gene 9 expression and its clinical significance in human testicular cancer
- The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Pathophysiology and Pharmacotherapy of Overactive Bladder